Hui-Yi Lin

Dr. Hui-Yi Lin

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2018 in Nature Genetics
Verified
Journal Article
Open access
PDF file
FSFredrick Schumacher
Fredrick Schumacher
AOAli Amin Al Olama
Ali Amin Al Olama
SBSonja I. Berndt
Sonja I. Berndt
SBSara Benlloch
Sara Benlloch
MAMahbubl Ahmed
Mahbubl Ahmed
C(Cancer Of The Prostate In Sweden (Caps)
Cancer Of The Prostate In Sweden (Caps)
Genome-wide association studies (GWAS) and fine-mapping efforts to date have identified more than 100 prostate cancer (PrCa)-susceptibility loci. We meta-analyzed genotype data from a custom high-density array of 46,939 PrCa cases and 27,910 controls of European ancestry with previously genotyped data of 32,255 PrCa cases and 33,202 controls of European ancestry. Our analysis identified 62 novel loci associated (P < 5.0 × 10−8) with PrCa and one locus significantly associated with early-onset PrCa (≤55 years). Our findings include missense variants rs1800057 (odds ratio (OR) = 1.16; P = 8.2 × 10−9; G>C, p.Pro1054Arg) in ATM and rs2066827 (OR = 1.06; P = 2.3 × 10−9; T>G, p.Val109Gly) in CDKN1B. The combination of all loci captured 28.4% of the PrCa familial relative risk, and a polygenic risk score conferred an elevated PrCa risk for men in the ninetieth to ninety-ninth percentiles (relative risk = 2.69; 95% confidence interval (CI): 2.55–2.82) and first percentile (relative risk = 5.71; 95% CI: 5.04–6.48) risk stratum compared with the population average. These findings improve risk prediction, enhance fine-mapping, and provide insight into the underlying biology of PrCa1.

27 March 2013 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
TIThe COGS–Cancer Research UK GWAS–ELLIPSE (part of GAME-ON) Initiative
The COGS–Cancer Research UK GWAS–ELLIPSE (part of GAME-ON) Initiative
RERosalind Eeles
Rosalind Eeles
TBThe Australian Prostate Cancer Bioresource
The Australian Prostate Cancer Bioresource
TOThe UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology
The UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology
TCThe UK ProtecT (Prostate testing for cancer and Treatment) Study Collaborators
The UK ProtecT (Prostate testing for cancer and Treatment) Study Collaborators
DEDouglas F Easton
Douglas F Easton

15 January 2009 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
MMMichael J. Mugavero
Michael J. Mugavero
HLHui-Yi Lin
Hui-Yi Lin
JWJames H. Willig
James H. Willig
AWAndrew O. Westfall
Andrew O. Westfall
KUKimberly B. Ulett
Kimberly B. Ulett
JAJeroan J. Allison
Jeroan J. Allison
Background.Dramatic increases in the number of patients requiring linkage to treatment for human immunodeficiency virus (HIV) infection are anticipat

14 September 2014 in Nature Genetics
Verified
Journal Article
Open access
PDF file
AOAli Amin Al Olama
Ali Amin Al Olama
ZKZsofia Kote-Jarai
Zsofia Kote-Jarai
SBSonja I Berndt
Sonja I Berndt
DCDavid V Conti
David V Conti
FSFredrick Schumacher
Fredrick Schumacher
CHChristopher A Haiman
Christopher A Haiman
Rosalind Eeles, Christopher Haiman and colleagues report genome-wide association and meta-analyses of prostate cancer in populations of European, African, Japanese and Latino ancestry. They identify 23 new susceptibility loci, including one associated with early-onset prostate cancer. Genome-wide association studies (GWAS) have identified 76 variants associated with prostate cancer risk predominantly in populations of European ancestry. To identify additional susceptibility loci for this common cancer, we conducted a meta-analysis of >10 million SNPs in 43,303 prostate cancer cases and 43,737 controls from studies in populations of European, African, Japanese and Latino ancestry. Twenty-three new susceptibility loci were identified at association P < 5 × 10−8; 15 variants were identified among men of European ancestry, 7 were identified in multi-ancestry analyses and 1 was associated with early-onset prostate cancer. These 23 variants, in combination with known prostate cancer risk variants, explain 33% of the familial risk for this disease in European-ancestry populations. These findings provide new regions for investigation into the pathogenesis of prostate cancer and demonstrate the usefulness of combining ancestrally diverse populations to discover risk loci for disease.

1 January 2009 in AIDS Patient Care and STDs
Verified
Journal Article
Closed access
KUKimberly B. Ulett
Kimberly B. Ulett
JWJames H. Willig
James H. Willig
HLHui-Yi Lin
Hui-Yi Lin
JRJustin S. Routman
Justin S. Routman
SASarah Abroms
Sarah Abroms
MMMichael J. Mugavero
Michael J. Mugavero
Following HIV diagnosis, linkage to outpatient treatment, antiretroviral initiation, and longitudinal retention in care represent the foundation for successful treatment. While prior studies have evaluated these processes in isolation, a systematic evaluation of successive steps in the same cohort of patients has not yet been performed. To ensure optimal long-term outcomes, a better understanding of the interplay of these processes is needed. Therefore, a retrospective cohort study of patients initiating outpatient care at the University of Alabama at Birmingham 1917 HIV/AIDS Clinic between January 2000 and December 2005 was undertaken. Multivariable models determined factors associated with: late diagnosis/linkage to care (initial CD4 < 350 cells/mm3), timely antiretroviral initiation, and retention across the first two years of care. Delayed linkage was observed in two-thirds of the overall sample (n = 567) and was associated with older age (odds ratio [OR] = 1.31 per 10 years; 95% confidence interval [CI] = 1.06–1.62) and African American race (OR = 2.45; 95% CI = 1.60–3.74). Attending all clinic visits (hazard ratio [HR] = 6.45; 95% CI = 4.47–9.31) and lower initial CD4 counts led to earlier antiretroviral initiation. Worse retention in the first 2 years was associated with younger age (OR = 0.68 per 10 years; 95% CI = 0.56–0.83), higher baseline CD4 count, and substance abuse (OR = 1.78; 95% CI = 1.16–2.73). Interventions to improve timely HIV diagnosis and linkage to care should focus on older patients and African Americans while efforts to improve retention should address younger patients, those with higher baseline CD4 counts, and substance abuse. Missed clinic visits represent an important obstacle to the timely initiation of antiretroviral therapy. These data inform development of interventions to improve linkage and retention in HIV care, an emerging area of growing importance.

10 July 2011 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
TOThe UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology
The UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology
ZKZsofia Kote-Jarai
Zsofia Kote-Jarai
TCThe PRACTICAL Consortium
The PRACTICAL Consortium
AOAli Amin Al Olama
Ali Amin Al Olama
GGGraham G Giles
Graham G Giles
RERosalind Eeles
Rosalind Eeles